Evidence map›Paper›PMID 32323781›Full record

ArticleOncology reports2020

MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.

Chen-Yang Meng, Zhen-Qun Zhao, Rui Bai, Wei Zhao, Yu-Xing Wang, Hui-Qin Xue, Liang Sun, Chao Sun, Wei Feng, Shi-Bing Guo

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Noncoding RNAs: the crucial role of programmed cell death in osteoporosis.Frontiers in cell and developmental biology · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Chen-Yang Meng *Department of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Zhen-Qun Zhao *Department of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Rui BaiDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Wei ZhaoDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Yu-Xing WangDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Hui-Qin XueDepartment of Rehabilitation, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Liang SunDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Chao SunDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Wei FengDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Shi-Bing GuoDepartment of Orthopedic Surgery, Second Affiliated Hospital of Inner Mongolia Medical University, Huimin, Hohhot, Inner Mongolia 010030, P.R. China.
Second Affiliated Hospital of Inner Mongolia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary malignant tumor of the bone affecting children and adolescents. Chemotherapy is now considered as a standard component of OS treatment, not only for children, but also for adults. However, chemoresistance continues to pose a challenge to therapy. Inhibition of autophagy has been demonstrated to decrease chemoresistance in OS. Moreover, microRNA‑22 (miR‑22) inhibits autophagy, leading to an improvement in the sensitivity of cisplatin (CDDP) in OS. The aim of the present study was therefore to investigate whether miR‑22 could mediate the CDDP resistance of OS cells by inhibiting autophagy via the phosphoinositide 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Cell proliferation assay, LC3 flow cytometry assay and monodansylcadaverine staining in MG63 cells and CDDP resistance cells (MG63/CDDP) were performed to explore to role of miR‑22 and CDDP in OS chemoresistance. Inoculation of tumor cells in an in vivo model, reverse transcription‑quantitative PCR (RT‑qPCR) assay, western blot analysis, and immunohistochemistry analysis were performed to investigate the role of miR‑22 and CDDP in the PI3K/Akt/mTOR pathway as it is affected by autophagy. The results revealed that miR‑22 inhibited the proliferation of MG63 and MG63/CDDP cells, and enhanced the anti‑proliferative ability of CDDP in vivo and in vitro. miR‑22 mediated the CDDP resistance of OS cells by inhibiting autophagy and decreasing CDDP‑induced autophagy via downregulation of the expression of PI3K, Akt, and mTOR at the mRNA level, and the expression of PI3K, phosphorylated (p)‑Akt, and p‑mTOR at the protein level. It was also convincingly demonstrated that miR‑22 mediates the CDDP resistance of OS by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Furthermore, in the MG63 cells that were affected by CDDP, the role of miR‑22 was shown to be similar to that of the investigated inhibitor of PI3K (wortmannin) in terms of regulating the PI3K/Akt/mTOR pathway, and wortmannin could also promote the effect of miR‑22. Interestingly, CDDP was demonstrated to induce autophagy by inhibiting the PI3K/Akt/mTOR pathway, whereas the pathway was upregulated in the state of chemoresistance. In conclusion, downregulation of the PI3K/Akt/mTOR pathway was shown to assist in the process of preventing chemoresistance.

Indexed as

AutophagyAnimalsAntineoplastic AgentsApoptosisBone NeoplasmsCell Line, TumorCell ProliferationCisplatinClass I Phosphatidylinositol 3-KinasesHumansMaleMiceMice, NudeMicroRNAsOsteosarcomaProto-Oncogene Proteins c-aktAKT1 protein, humanAntineoplastic AgentsCisplatinClass I Phosphatidylinositol 3-KinasesMicroRNAsMIRN22 microRNA, humanMTOR protein, humanPIK3CA protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesautophagychemoresistancecisplatinmicroRNA-22osteosarcoma

Identifiers

PMID32323781
PMCPMC7057943
OpenAlexW3004588481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.